Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19
Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’...
Saved in:
| Main Authors: | Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, Joel Chuku |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01145-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
by: Adewunmi Akingbola, et al.
Published: (2025-12-01) -
Chandipura Virus Resurgence in India: Insights Into Diagnostic Tools, Antiviral Development, and Public Health Implications
by: Adewunmi Akingbola, et al.
Published: (2025-01-01) -
Understanding the resurgence of mpox: key drivers and lessons from recent outbreaks in Africa
by: Adewunmi Akingbola, et al.
Published: (2025-04-01) -
Coupling mechanisms coordinating mRNA translation with stages of the mRNA lifecycle
by: Valeria Famà, et al.
Published: (2025-12-01) -
Protocol to distinguish pre-mRNA from mRNA in RNA-protein interaction studies
by: Christina Zeiler, et al.
Published: (2025-09-01)